

Venous malformation and haemangioma: differential diagnosis, diagnosis, natural history and consequences

B B Lee

Center for the Lymphedema and Vascular Malformations, George Washington University, Washington, DC, USA

Abstract

Venous malformation (VM) is the most common form of congenital vascular malformation (CVM). VM presents at birth as an inborn vascular defect and never disappears/regresses spontaneously through the rest of life; it will continue to grow slowly at a rate that is proportional to the growth rate of the body. Haemangioma is *not* a vascular malformation but one of the vascular tumours originating from the endothelial cells; it develops after birth mostly in the infantile/neonatal period with a distinctive growth cycle: a proliferation phase of early rapid growth followed by an involutional phase of slow regression. Although the vascular malformation and vascular tumour belong to the 'vascular anomaly' together, both conditions are fundamentally different not only in their anatomical, histological and pathophysiological findings but also in their clinical courses. Therefore, an appropriate differential diagnosis of the VM is mandated not only from other kinds of CVMs but also from 'genuine' haemangioma. Appropriate diagnosis and assessment of VMs can be made based on clinical presentation and a proper combination of basic non-invasive studies in general but the presence of a mixed lesion involving other types of CVM lesions and the type of VM lesion, extratruncular and truncular, will dictate the need for further work-up with additional non- to less-invasive study or angiography. Otherwise, angiography is usually reserved for therapeutic planning and treatment.

Keywords:

Introduction

Venous malformation (VM) is one of the congenital vascular malformations (CVMs) known as an enigma of modern medicine through the century.¹⁻⁴ Such a notorious reputation was partly due to so many name-based eponyms (e.g. Klippel Trenaunay Syndrome, Parkes-Weber Syndrome, Sturge-Weber Syndrome) attempting to define such a complex vascular condition will only add to the confusion.

Name-based eponyms were used in the past to define various vascular malformations but due to

the absence of a standardized classification system they often misled with regard to the underlying defect in these inborn errors.⁵⁻⁸ For example, in the early 20th century many physicians including two French physicians, Klippel and Trenaunay, reported a unique condition of CVMs characterized by a syndrome of skin, soft tissue, bone and blood vessel lesions.⁹

With limited anatomical and pathophysiological knowledge due to the absence of appropriate diagnostic studies (e.g. angiography) then, these conditions were classified solely based on clinical findings and named after the describing physician (e.g. Servelle and Martorell syndrome).¹⁰

Although these name-based eponyms have been used extensively for many decades to classify various CVMs, these eponyms failed to provide essential information regarding the aetiology, anatomy and pathophysiology of these complex vascular conditions.^{11,12}

Correspondence: **B B Lee MD PhD FACS**, Center for the Lymphedema and Vascular Malformations, George Washington University, Washington, DC, USA.
Email: bblee38@gmail.com

Accepted XX XXXX

Nevertheless, each syndrome has important historical significance providing a clinical description of the primary vascular lesion along with its secondary non-vascular lesions and their clinical findings (soft tissue swelling, long bone growth discrepancy, etc.). These eponyms are still useful for certain combined forms of vascular malformations, although its role has been largely replaced by the newer classifications: ISSVA Classification^{1,13,14} and (modified) Hamburg Classification.^{6,7,12,15,16}

ISSVA Classification classified the CVMs as one of two 'Vascular Anomaly' components together with Vascular Tumour which is represented by the neonatal or infantile haemangioma,^{17,18} and the CVMs were further classified based on the haemodynamic/flow status (Table 1). The Hamburg Classification classified all the CVMs based on its predominant type (e.g. venous, lymphatic and arterio-venous [AV] malformation) first and made a further subclassification of the CVMs based on the embryological characteristics of each malformation (Table 2).

These two abnormal vascular conditions: CVMs and vascular tumours/haemangiomas, however, are fundamentally different, not only in their anatomical, histological and pathophysiological findings, but also in their clinical courses, which emphasize the importance of a precise understanding of these two different conditions.

Therefore, proper understanding of the CVMs as a whole is mandated for VM diagnosis together with its differential diagnosis from haemangioma.

Definition and classification of CVM

CVM is an inborn vascular defect as the outcome of developmental arrest during embryogenesis¹⁹⁻²² and presents at birth as various conditions of malformed vessels; it continues to grow at a rate that is proportional to the growth rate of the body regardless of its type.

Table 1 ISSVA* Classification of vascular anomalies, 1996, Rome, Italy

Tumours	Vascular malformation	
	Simple	Combined
Haemangioma	Capillary malformation (CM)	CVM
Other tumours	Lymphatic malformation (LM)	CLVM
	Venous malformation (VM)	LVM
	Arterio-venous malformation (AVM)	CAVM CLAVM

*ISSVA, International Society for the Study of Vascular Anomalies

Table 2 The modified Hamburg classification of congenital vascular malformations

Primary classification*	168
Arterial malformations	169
Venous malformations	170
Arteriovenous malformations	171
Lymphatic malformations	172
Capillary malformations	173
Combined vascular malformations	174
Anatomical/Embryological subclassification†	175
Extratruncular forms	176
Diffuse, infiltrating	177
Limited, localized	178
Truncular forms	179
Obstruction or narrowing	180
Aplasia; Hypoplasia; Hyperplasia	181
Obstruction due to atresia or membranous occlusion	182
Stenosis due to coarctation, spur or membrane	183
Dilation	184
Localized (aneurysm)	185
Diffuse (ectasias)	186

*Based on predominant vascular structure in the malformation

†Based on anatomy and developmental arrest at different stages of embryonal life: extratruncular form from earlier stages (no named vessels); truncular form from late stage (major named vessels)

VM is one of the most common CVMs, where defective development is limited to the venous system (Figures 1a and c).

Infantile or neonatal haemangioma, on the other hand, is a vascular tumour that originates from endothelial cells, and has no relationship with defective development. It usually appears in the early neonatal period. It has a distinctive growth cycle characterized by a proliferation phase of early rapid growth followed by an involutonal phase of slow regression. Unlike CVMs, haemangiomas undergo self-limited growth followed by a subsequent involution that usually occurs before the age of 5-10 years in the majority of cases^{13,14,17,18} (Figures 2a and d).

The terms 'capillary or cavernous haemangioma', which were originally used to define the location of infantile or neonatal haemangioma, has been erroneously used to describe VM lesions. However, the terms 'capillary or cavernous haemangioma' should no longer be used in order to avoid confusion between (a genuine) haemangioma and vascular malformation and prevent an incorrect diagnosis.^{11,12}

'Angiodysplasia' is another popular older term used to describe CVMs but this term also has limited scope and utility, adding significant confusion to the classification so that it should be replaced with a correct term 'Congenital Vascular Malformation.'




Figure 1 Panel a presents a venous malformation (VM) affecting the entire left lower extremity with significant symptoms; it is a diffuse infiltrating 'extratruncular' lesion possessing mesenchymal cell characteristics of steady growth. Panel b shows spontaneous collapse of the VM lesion when the leg is elevated (a), typical of a pure VM, is a significant clue to support its nature as predominantly VM in contrast to other kinds of congenital vascular malformations. Panel c illustrates positive evidence of abnormal blood pooling along the lesion by WBBPS (whole body blood scintigraphy) to confirm the lesion as VM (from Lee *et al.*¹²)

The Hamburg Classification classified the CVMs into five different types based on its predominant vascular malformation component: arterial malformation (AM),^{23,24} VM,¹⁻⁴ AV-shunting malformation (AVM),^{25,26} lymphatic malformation (LM)^{27,28} and combined vascular malformation. The most common combined (or mixed) malformation is haemolymphatic malformation (HLM)^{29,30} (Table 2).

The initial consensus, however, did not include capillary malformation (CM) in the classification since the lesion was believed to lack clinical significance and clinically was not equivalent to other CVMs. However, the CM was later included in the classification at the Denver consensus meeting in 1992⁸ and at the Seoul consensus meeting in 1996.^{31,32}

Each vascular malformation is further subclassified into one of two forms, based on its embryological development stage, as either an Extratruncular or a Truncular form (Table 2). The clinical behaviour of every vascular malformation is dependent on its unique embryological characteristics, specifically, the stage of embryogenesis at which developmental arrest occurs. This results in a wide range of clinical presentations, unpredictable clinical course and erratic response to treatment with the potential for high rates of recurrence among the extratruncular lesions.^{33,34}

The 'extratruncular form' of CVM lesions arises when developmental arrest occurs in the 'earlier stage' of embryonic life while the vascular system is in the reticular stage. Extratruncular lesions are embryonic tissue remnants of mesodermal origin

that retain the characteristics of the mesenchymal cells (angioblasts). It retains its potential to grow and proliferate when stimulated internally (e.g. menarche, pregnancy and hormone) or externally (e.g. trauma, surgery).^{20-23,35-37} These lesions, therefore, carry a significant risk of recurrence, especially after suboptimal treatment.

Extratruncular lesions often present as either a (diffuse) infiltrating lesion or a limited lesion causing mechanical compression to surrounding tissues and organs in addition to their haemodynamic impact.

The 'truncular form' of CVM lesions arises when developmental arrest occurs during the vascular trunk formation period in the 'later stage' of embryonic development.^{20-23,35-37} Truncular lesions have lost the embryonic characteristics of the mesenchymal cells along with the potential to grow and proliferate. Thus, these lesions carry minimal risk of recurrence.

Truncular lesions, however, are associated with more serious haemodynamic consequences related to the type of CVM (e.g. marginal and embryonic veins as truncular VM). These lesions often present as a persistent fetal remnant (truncular) vessel³⁸⁻⁴⁰ that failed to involute normally (e.g. sciatic vein), or as a defective vessel trunk (e.g. vein web, venous aneurysm).⁴¹⁻⁴⁴

The truncular lesion is further subgrouped as an obstructive or a dilated lesion. However, all truncular lesions are involved in a 'formed' vessel with various degrees of defective development (e.g. agenesis/rudimentary deep vein) ranging from incomplete or immature lesions (aplasia




Figure 2 Panel depicts clinical condition of (infantile) haemangioma as rapidly expanding lesion along the right cheek, first noted a few months after birth, which may be mistaken for a venous malformation (VM). Panels b and c show typical magnetic resonance imaging findings of (infantile) haemangioma, affecting right cheek with prominent vascularity that helps differentiate it from common VM. Panel d presents duplex ultrasonographic findings of active/high blood flow through the lesion in contrast to what would be found in a VM lesion (from Lee *et al.*¹²)

or hypoplasia) to overdeveloped lesions (hyperplasia).

The Hamburg Classification provides clinicians with the most critical information regarding this embryological status of various vascular malformations. Embryological subclassification into one of two different subtypes, truncular or extratruncular, allows clinicians to predict the clinical course, response to treatment and likelihood of recurrence.^{1,12}

The ISSVA classification system based on the haemodynamic status of the CVM was introduced by Mulliken *et al.*^{13,14} Using the traditional name based eponyms, CVMs are further classified as

'fast flow' and 'slow flow' lesions. This flow-based classification is useful from a clinical management point of view but remains confusing and cumbersome due to its combination with various traditional name-based eponyms; the continued use of name-based nosology and syndrome-based classification allows further confusion with current classification systems. Besides, the AVMs are classified to 'AV malformation and AV fistula' despite malformation in 'fistulous' condition to allow AV shunting. Currently, many specialists across the Atlantic have adopted parts of this classification system and have combined it with the Hamburg Classification.

Diagnosis of CVMs

A new concept on the CVM mandated a precise diagnosis to provide accurate information on its histo-pathological, haemodynamic and embryological characteristics; this new information in turn allowed a new prospect to its management with a new view.

Now we know there are many different vascular malformations with different clinical significances and we no longer consider them as an enigma since we have enough knowledge to verify many different aspects of each CVM lesion either existing alone or as combined with other CVMs.^{1,12}

Many newly developed tests, mostly non-invasive, can now provide precise diagnosis of each CVM to confirm the clinical impression.^{45,46}

The diagnosis *per se* is now feasible only with limited combinations of a few non- to less-invasive tests in the majority of CVMs: duplex ultrasonography,^{47,48} magnetic resonance imaging (MRI),^{49,50} whole body blood pool scintigraphy (WBBPS),^{51,52} transarterial lung perfusion scintigraphy (TLPS)^{53,54} and radionuclide lymphoscintigraphy,^{55–58} etc. (Table 3).

The invasive tests (e.g. arteriography, phlebography) in general are seldom needed for the diagnosis *per se*, and could be saved till needed as a road map for the treatment except differential diagnosis with haemangioma or AVM.^{1,46}

Precise defining of the type (e.g. VM, LM, HLM and AVM) and nature (e.g. truncular or extratruncular lesion) of each CVM involved should follow a detailed assessment of its extent, severity and its

Table 3 Diagnostic tests for venous malformation

I. Non- to less-invasive studies

Magnetic resonance–T2-weighted image (MRI) study
Duplex ultrasonography
Whole body blood pool scintigraphy (WBBPS): transvenous angioscan utilizing radioisotope-tagged red blood cells
Transarterial lung perfusion scintigraphy (TLPS)*: transarterial angioscan utilizing radioisotope-tagged microsphere albumin
Air plethysmography
MR venography (MRV) and/or MR arteriography (MRA)*
Computerized tomographic (CT) study with contrast and 3D reconstruction
Radioisotope (RI) lymphoscintigraphy*
Ultrasound lymphangiography*
MR lymphangiography*

II. Selective invasive studies

Ascending, descending and/or segmental venography
Percutaneous direct puncture phlebography
Standard and/or selective arteriography*
Percutaneous direct puncture lymphangiography*

*Optional for differential diagnosis of AVM and LM

secondary impact on the related systems/organs, which is also now feasible with non- to less-invasive tests alone in its majority.^{12,46,59}

Differential diagnosis with haemangioma

True haemangioma is a vascular tumour belonging to the vascular anomaly together with vascular malformation; the female to male ratio is 3 to 5:1. Haemangioma is usually not present at birth and generally appears suddenly during the early neonatal period as a rapidly growing tumour. However, haemangioma has a distinctive pattern of self-limited growth as previously mentioned, with initial rapid growth during the early proliferate phase followed by slow regression through the long involution phase. It is generally resolved spontaneously with minimum morbidity before reaching the age of 7–9 years.^{13,14,17,18,60,61}

In contrast, a CVM lesion is always present at birth (even though initially it may not be apparent) and generally distinctive on birth as an inborn error; they all steadily grow commensurably in proportion to general/systemic body growth unless complicated (e.g. bleeding, infection); it never disappears nor regresses. It carries an equal gender distribution.

The haemangioma occurs in the range of 2–3% among newborns and then steadily increases to about 10% by the end of the first year of life. However, the incidence of CVM is reported to be 1.2% by Tasnadi *et al.*⁶² This is higher than other congenital malformations (e.g. congenital hip dislocation and dysplasia).

Therefore, when a vascular anomaly is first identified during the neonatal period, the differential diagnosis should include both CVM and haemangioma, which is often specified as either neonatal or infantile haemangioma (Figure 2).

In most cases, a careful history and physical examination provide enough data to clinically distinguish a vascular malformation and haemangioma. Distinction between the two diagnoses is often made using additional non-invasive laboratory studies (e.g. duplex ultrasonography). These studies are useful especially for a deeply seated haemangioma mimicking VM. Tissue biopsy is useful in situations where the D.D. includes sarcoma.¹

Differential diagnosis with other CVMs

Once haemangioma is excluded and a diagnosis of CVM is confirmed, further characterization of the

type of CVM is the next step.^{1,12} The VM remains the most common type of CVM. VM lesions occur as a pure VM or as a mixed lesion combined with other types of CVMs which include CM, LM and AVM as mentioned above.^{12,46,63}

The majority of VM lesions are pure/predominant VM lesions with no other circulation systems involved. However, approximately 15–20% of VMs are mixed lesions, and most frequently combined with LM and CM, often known as Klippel–Trenaunay Syndrome (KTS)^{64,65} (Figure 3). When the VM lesion is further combined with AVM besides LM and CM, this mixed lesion is often called Parkes-Weber Syndrome (PWS).^{66,67}

The presence of an occult AVM, therefore, must be determined when the VM presents as a mixed type in view of the virulent nature of AVMs. AVM lesions compared with VM lesions are more destructive, exhibit unpredictable behaviour and carry high morbidity. TLPS is a study useful for diagnosing and screening for the presence of an AVM. This study also assesses the extent of shunting of cardiac output through the AVM lesion when located in an extremity.^{53,54}

Diagnosing the presence of an LM^{68,69} is not as critical as it is with an AVM for the HLM cases. However, the presence of an LM lesion cannot be always determined by MRI alone; LM lesions are sometimes indistinguishable from VM lesions




Figure 3 Panel a presents clinical appearance of VM (venous malformation) lesion affecting the right lower extremity as a haemolympathic malformation, mixed with lymphatic malformation and capillary malformation, often known as Klippel–Trenaunay syndrome. Panel b depicts magnetic resonance imaging finding of extratruncular VM lesion diffusely infiltrating in the soft tissue and muscles of right lower extremity. Panel c shows WBBPS (whole body blood pool scintigraphy) findings of massive abnormal blood pool throughout entire right lower extremity; this WBBPS effectively ruled out any additional lesions throughout the body. Panel D illustrates transarterial lung perfusion scintigraphy study that is negative for abnormal AV shunting – 2.9% is within normal range. Panel e delineates radionuclide lymphoscintigraphy findings of anatomically normal, but functionally abnormal double (deep and superficial) lymphatic transporting vessel, visualized along right lower extremity. This finding is consistent with a clinical finding of chronic lymphoedema secondary to hypoplasia of the superficial lymphatic system which is well compensated by the deep system (from Lee *et al.*⁴⁶)

661 even on MRI. However, T2-weighted MRI imaging
662 remains the gold standard in diagnosis of VM
663 **Q5** lesions (5). VM lesions are readily detected on
664 WBBPS (Figures 2 and 3)

665 WBBPS utilizes radioisotope-tagged red blood
666 cells to detect abnormal blood pooling in VM
667 lesions (with blood volumes as little as 1.0 mL)
668 throughout the body when present.^{51,52} LM
669 lesions are not detected with WBBPS. Thus, the
670 combination of T2-weighted MRI imaging and
671 WBBPS will allow accurate diagnosis of a VM
672 lesion combined with an LM lesion.

673 Percutaneous aspiration (using ultrasound
674 guidance or direct puncture) and fluid analysis
675 of a mixed VM and LM lesion is also useful in deter-
676 mining the nature of the lesion.

677 **Diagnosis of VM**

680 After the diagnosis of a VM lesion is made, further
681 identification of its subtype as extratruncular or
682 truncular is required in order to identify its embry-
683 logical and haemodynamic characteristics. Both
684 extratruncular and truncular VM lesions have dis-
685 tinctively different characteristics regarding its
686 natural history and clinical behaviour.^{20–23, 35,36,37}

687 **Extratruncular VM lesions**

689 These lesions naturally carry a high risk of recur-
690 rence if not treated radically on the contrary to trunc-
691 ular lesions due to their unique evolutionary power
692 to grow when the condition should meet as men-
693 tioned previously.

694 Extratruncular lesions are further subdivided
695 into diffuse, infiltrating type and localized, limited
696 type. Diffuse, infiltrating extratruncular lesions
697 may cause symptoms due to compression of the sur-
698 rounding structures (bones, muscles and nerves).
699 They have a notorious reputation by namely pain
700 due to embryological proximity of nerves and
701 veins. They may also produce significant haemo-
702 dynamic impact on the involved venous system
703 that is dependent on lesion size and location.

704 **Truncular VM lesions**

705 These lesions (e.g. popliteal vein aneurysm or
706 ectasia, femoral vein hypoplasia and iliac vein agen-
707 esis) no longer exhibit their embryonic character-
708 istics and lack the potential for proliferation on
709 the contrary to extratruncular lesions.

710 However, truncular lesions have haemody-
711 namic consequences due to congenital valvular

712 incompetence, obstruction (atresia, hypoplasia)
713 or dilation/aneurysm formation with associated
714 risk of thromboembolism (e.g. marginal vein [MV]).

715 Truncular lesions can be subdivided into aplasia
716 or hypoplasia,^{41,70,71} as well as obstruction, or
717 dilation/aneurysms.^{44,72,73} Immature/incomplete/
718 abnormal development of the main axial veins
719 result in aplasia, hypoplasia or hyperplasia of the
720 vessel (e.g. agenesis/rudimentary femoral vein) or
721 as a defective vessel: obstruction (e.g. vein web,
722 spur, annulus or septum) or dilation (e.g. popliteal
723 or iliac vein ectasia/aneurysm).

724 One of the unique truncular VM lesions is persist-
725 ent embryonic veins such as the MV or the sciatic
726 vein when a fetal (truncal) vessel fails to undergo
727 normal involution.^{38–40, 74}

728 Truncular lesions of obstructive nature (webs,
729 hypoplasia) may have different haemodynamic
730 impacts on their relevant venous systems de-
731 pending upon their location, extent/severity and
732 natural compensation through collaterals. Chronic
733 venous insufficiency develops in the territory
734 drained by the truncular vein. Stenosing truncular
735 lesions produce venous obstruction leading to a
736 reduction in venous drainage. Membranous ob-
737 struction of the (suprahepatic) inferior vena cava
738 in primary Budd–Chiari syndrome is an example
739 of a primary obstructive VM affecting a major
740 vein.^{42,43}

741 Truncular VM lesions may also occur in
742 veins with the same embryological origin or
743 draining the same territory (e.g. stenosing lesions
744 of the extracranial jugular veins, superior vena
745 cava, and azygos vein system along the main
746 outflow pathways of the cerebro-spinal venous
747 system).^{75,76}

748 Avalvulia, or absence of valves, is another form of
749 hypoplasia that produces venous reflux. Together
750 with atresia of the venous trunks and venous aneur-
751 ysms, they are relatively common. The incidence of
752 aneurysm has been reported to be 4% in nearly 490
753 cases of congenital anomalies of the venous
754 system.^{41,77,78}

755 **Diagnostic evaluation of VM**

756 **Clinical evaluation**

757 The diagnosis of a VM, both extratruncular and
758 truncular subtypes, can often be made with a
759 careful history and physical examination alone.
760 Therefore, proper clinical evaluation of patients
761 with VMs is essential. A thorough history, including
762 a detailed birth and family history, must be taken.

771 VM lesions occur throughout all areas of the
772 body, and therefore complete examination of all
773 skin surfaces including the genitalia is essential.
774 Patients should also be examined in the standing
775 position and posture and gait evaluated to assess
776 the dynamic impact of the VM lesion. Limb length
777 discrepancy (with and without pelvic tilt) and com-
778 pensatory scoliosis will probably not be missed on
779 examination with this approach.⁷⁹⁻⁸¹

780 The physical examination should include careful
781 assessment (inspection, palpation and auscultation)
782 of both the arterial and venous systems including a
783 detailed pulse exam, making a note of any oedema,
784 skin changes, varicosities, pigmentation or ulcera-
785 tions. An enlarged or longer extremity, digital
786 anomalies and asymmetric growths of any part of
787 the body must be recorded.

788 The 'limb elevation test' should also be per-
789 formed for all extremity VM lesions. In this test,
790 the VM lesion bearing limb demonstrates a
791 reduction in both limb and lesion swelling with
792 leg elevation (Figure 2).

793 Furthermore, initial baseline evaluation should
794 include an assessment of VM lesion associated
795 acute complications (e.g. superficial and deep vein
796 thrombosis [DVT], pulmonary embolism [PE]) and
797 chronic complications and sequelae (e.g. limping
798 and scoliosis with pelvic tilt). An accurate record
799 of these findings is useful for regular periodic
800 follow-up after treatment.^{1,34,46}

801 Assessment of direct and/or indirect secondary
802 effects of the primary VM lesion on various organ
803 systems (e.g. bone, soft tissue and muscles)
804 should be performed using comprehensive clinical
805 evaluation and appropriate laboratory studies
806 especially in situations where the VM lesion exists
807 as an HLM lesion. Appropriate assessment of the
808 involved organ systems such as the gastrointestinal
809 system (e.g. GI bleeding and malabsorption
810 syndrome), cardiopulmonary system (e.g. pleural
811 effusion), musculoskeletal system (e.g. long bone
812 length discrepancy, scoliosis and pelvis tilt) and
813 genitourinary system (e.g. lymph leak) will
814 require involvement of additional surgical special-
815 ties.

816 Abnormal long bone growth as a consequence
817 of intraosseous and extraosseous VM lesions in-
818 volvement should be evaluated routinely with
819 appropriate radiological studies.⁷⁹⁻⁸¹

820 Confirmation of the presence of a VM lesion
821 is usually made with a combination of various
822 non-invasive to minimally invasive studies
823 which include Duplex ultrasonography, MRI and
824 WBBPS as described above. The minimally invasive
825 studies are generally adequate to diagnose and

826 assess the extent and severity of the VM lesion
827 prior to treatment (Table 3).
828
829

Non-invasive tests

830 Duplex scanning is the first diagnostic test of choice
831 for non-invasive evaluation of all patients with
832 VMs, involving the limbs, to assess the deep and
833 superficial veins, to identify any aberrant vein,
834 obstruction, dilation or valvular incompetence and
835 define the feeding artery or draining veins of the
836 VM (Table 3).^{47,48,82,83}

Q6

837 Other non-invasive studies, such as plethysmo-
838 graphy, segmental pressure measurement and
839 pulse volume recordings should be used selectively
840 and clinical correlations with abnormal findings
841 (e.g. outflow obstruction) need to be established.¹

842 Standard plain X-ray is still useful to identify
843 abnormal findings in the soft tissue, and other
844 malformation-related abnormalities along the skel-
845 etal system. It is also useful to detect the phlebolith
846 to confirm the diagnosis of VM.
847

Minimally invasive tests

Computed tomography with intravenous contrast^{1,84,85}

850 Computerized tomographic venography is rec-
851 ommended for evaluation of obstructed veins and
852 other truncular anomalies of large veins in the
853 chest, abdomen or pelvis (Table 3). Computed tom-
854 ography accurately identifies the underlying path-
855 ology, confirms venous obstruction or extrinsic
856 compression and delineates anatomical variations
857 and extent of venous thrombosis.⁸⁶

MRI and MR angiography^{49,50,87,88}

861 MR imaging and MR venography are recom-
862 mended for evaluation of VMs. The test is reliable;
863 it confirms the extent and type of the VM, delineates
864 feeding and draining vessels, distinguishes
865 between different soft tissues (muscle, fat) and the
866 vascular structures. The imaging modality is
867 highly accurate in diagnosis of DVT.⁸⁶

WBBPS: transvenous angioscan utilizing radioisotope-tagged red blood cells^{51,52,89,90}

870 WBBPS is an optional test to screen for multiple VM
871 lesions scattered throughout the body. It allows
872 qualitative and quantitative evaluation of the VM
873 lesion especially during the course of multisession
874 sclerotherapy as a cost-effective measure. It is an
875 excellent tool for routine follow-up and to assess
876 the progress of treatment and the natural course
877 of the VM lesion. It can exclude a combined
878
879
880

VM–LM where the absence of an abnormal blood pool over the lymphatic lesion is the typical finding.

TLPS: transarterial angioscan utilizing radioisotope-tagged microsphere albumin^{53,54}

TLPS is not indicated for evaluation of the VM lesion. Its major function is to rule out the presence of a combined AVM lesion. TLPS can detect microshunting of an AVM lesion which can often be missed on conventional arteriography.

Invasive tests

Selective invasive study (e.g. arteriography and phlebography) is often not needed for routine diagnosis of the VM lesions as mentioned previously and can be reserved for therapeutic planning and treatment (Table 3). Arteriography and venography may be required in the setting of a mixed VM lesion to determine and assess the nature of the CVM components. This is especially true for a mixed VM lesion combined with an AVM.⁸

However, invasive tests may be required for diagnosis when non- to minimally invasive tests (e.g. computerized tomographic and/or MRI) fail to confirm the diagnosis or to delineate important diagnostic details.

For example, an obstructive truncular VM lesion along the iliac vein often needs more precise anatomical information. Ascending phlebography combined with IVUS studies is essential for proper management. Descending phlebography is an indispensable tool to assess deep venous reflux along the pelvic veins and/or sciatic veins.^{91–93}

Direct puncture phlebography is also very useful to identify a large efferent vein of extratruncular lesions.

In the paediatric age group less than two years old, only minimum necessary diagnostic procedures (usually non-invasive studies) are indicated in general to confirm the lesions as the VMs and rule out the AVM lesion. Complete assessment with angiography is often not required and if needed, can often be delayed until the child is older or fully grown. Angiography is required for urgent and immediate treatment in the rare occasion when a VM lesion is located in a life-threatening area which compromises normal functions (e.g. seeing, breathing, hearing, and eating) or is limb threatening.

Diagnosis of VM-coagulopathy

A potential risk of coagulopathy beyond pain has been largely neglected despite new evidence which

shows this pain/ache along the VM lesion is closely linked to ‘intravascular coagulation phenomenon’ together with the phleboliths. The pain is a further warning sign for increased risk of more serious complication (e.g. venous thromboembolism) and subsequent morbidity to cause extensive damage throughout its natural course.^{94–97}

Among the many types of truncular VM lesions, the lateral embryonic or MV in particular accompanies quite high risk of DVT and PE, which is often fatal.^{38–40,74} Together with its counterpart, extratruncular VM lesions, MV causes various degrees of pain and thrombosis within a lesion resulting in PE besides severe bleeding especially during surgical procedures.

A ‘localized intravascular coagulopathy’^{98,99} is the most common form of coagulopathy involved in the VM so that proper understanding on this coagulation issue remains essential for diagnosis and management of VM.

Coagulation profile and D-dimer levels are particularly indicated for extensive VM lesions.^{100–103} The following laboratory studies form an essential part of the patient’s work-up:

- D-dimer-quantitative assay;
- Fibrinogen;
- Platelet count;
- PT, APTT;
- Thrombophilia screening for high-risk malformations (e.g. lesions involving the orbit) (in the presence of thrombophilia and depending on the risk of the specific procedure, adequate anticoagulation should be provided).

Coagulation studies are not routinely included in the evaluation of extratruncular VM lesions. However, scattered phleboliths combined with extensive VM lesions are generally indicated for a full coagulation study especially when the treatment is planned. The finding of consumptive thrombocytopenia and leucopenia would need further coagulation study to decide anticoagulation therapy.

Conclusion

VM lesions often occur as mixed lesions involving other types of CVM lesions. The presence of a mixed lesion and the type of lesion present will dictate the need for further work-up and non-invasive study or angiography.

Appropriate diagnosis and assessment of VMs can be made based on clinical presentation and

non-invasive investigations. Angiography is usually reserved for therapeutic planning and treatment.

References

- Lee BB, Bergan J, Gloviczki P, et al. Diagnosis and treatment of venous malformations – Consensus Document of the International Union of Phlebology (IUP)-2009. *Int Angiol* 2009;**28**:434–51
- Lee BB, Bergan J. Transition from alcohol to foam sclerotherapy for localized venous malformation with high risk. In: Bergan J, Cheng V L eds. *A Textbook – Foam Sclerotherapy*. Chapter 12. London, UK: The Royal Society of Medicine Press Ltd, 2008:129–39
- Lee BB, Kim DL, Huh S, et al. New experiences with absolute ethanol sclerotherapy in the management of a complex form of congenital venous malformation. *J Vasc Surg* 2001;**33**:764–72
- Lee BB, Do YS, Byun HS, Choo IW, Kim DI, Huh SH. Advanced management of venous malformation (VM) with ethanol sclerotherapy: mid-term results. *J Vasc Surg* 2003;**37**:533–8
- Malan E. History and Nosography. In: Malan E, ed. *Vascular Malformations (Angiodysplasias)*. Milan, Italy: Carlo Erba Foundation, 1974:5–19
- Belov S. Classification, terminology, and nosology of congenital vascular defects. In: Belov S, Loose DA, Weber J, eds. *Vascular Malformations*. Reinbek, Germany: Einhorn-Press, 1989:25–30
- Belov St. Classification of congenital vascular defects. *Int Angiol* 1990;**9**:141–6
- Rutherford RB. Editorial introduction. *Semin Vasc Surg* 1993;**6**:197–8
- Klippel M, Trenaunay J. Du noevus variqueux et osteohypertrophique. *Arch Gén Méd* 1900;**3**:641–72
- Gibbon WW, Pooley J. Pathological fracture of the femoral shaft in a case of Servelle-Martorell syndrome (phleboeclatic osteohypoplastic angiodysplasia with associated arterio-venous malformation. *Br J Radiol* 1990;**63**:574–6
- Lee BB, Laredo J. Hemangioma and venous/vascular malformation are different as an apple and orange! Editorial. *Acta Phlebol* 2012;**13**:1–3
- Lee BB, Laredo J, Lee TS, Huh S, Neville R. Terminology and classification of congenital vascular malformations. *Phlebology* 2007;**22**:249–52
- Mulliken JB. Treatment of hemangiomas. In: Mulliken JB, Young AE, eds. *Vascular Birthmarks, Hemangiomas and Malformations*. Philadelphia, PA: WB Saunders, 1988:88–90
- Enjolras O, Wassef M, Chapot R. *Color Atlas of Vascular Tumors and Vascular Malformations*. Cambridge University Press
- Rutherford RB. Classification of peripheral congenital vascular malformations. In: Ernst C, Stanley J, eds. *Current Therapy in Vascular Surgery*. 3rd edn. St Louis, MO: Mosby, 1995:834–8
- Belov ST. Anatomopathological classification of congenital vascular defects. *Semin Vasc Surg* 1993;**6**:219–24
- Mulliken JB. Cutaneous vascular anomalies. *Semin Vasc Surg* 1993;**6**:204–18
- Mulliken JB, Young AE, eds. *Vascular Birthmarks: Hemangiomas and Malformations*. Philadelphia, PA: WB Saunders, 1988
- Lee BB. Critical issues on the management of congenital vascular malformation. *Ann Vasc Surg* 2004;**18**:380–92
- Bastide G, Lefebvre D. Anatomy and organogenesis and vascular malformations. In: Belov St, Loose DA, Weber J, eds. *Vascular Malformations*. Reinbek: Einhorn-Press Verlag GmbH, 1989:20–2
- DeTakats G. Vascular anomalies of the extremities. *Surg Gynecol Obstet* 1932;**55**:227–37
- Woolard HH. The development of the principal arterial stems in the forelimb of the pig. *Contrib Embryol* 1922;**14**:139–54
- Agrawal A, Whitehouse R, Johnson RW, Augustine T. Giant splenic artery aneurysm associated with arterio-venous malformation. *J Vasc Surg* 2006;**44**:1345–9
- Miele VJ, Rosen CL, Carpenter J, Rai A, Bailes JE. Vertebral artery-to-middle cerebral artery bypass with coil embolization of giant internal carotid artery aneurysm: technical case report. *Neurosurgery* 2005;**56**:E1159
- Lee BB, Lardeo J, Neville R. Arterio-venous malformation: how much do we know? *Phlebology* 2009;**24**:193–200
- Lee BB, Laredo J, Deaton DH, Neville RF. Arterio-venous malformations: evaluation and treatment. In: Gloviczki P, ed. *Handbook of Venous Disorders: Guidelines of the American Venous Forum*. Chapter 53, 3rd edn. London, UK: A Hodder Arnold, 2009:583–93
- Lee BB, Kim YW, Seo JM, et al. Current concepts in lymphatic malformation (LM). *Vasc Endovasc Surg* 2005;**39**:67–81
- Lee BB, Laredo J, Seo JM, Neville R. Hemangiomas and vascular malformations. In: Mattassi, Loose, Vaghi, eds. *Treatment of Lymphatic Malformations*. Chapter 29. Milan, Italy: Springer-Verlag Italia, 2009:231–50
- Jacob AG, Driscoll DJ, Shaughnessy WJ, Stanson AW, Clay RP, Gloviczki P. Klippel-Trenaunay syndrome: spectrum and management. *Mayo Clin Proc* 1998;**73**:28–36
- Gloviczki P, Stanson AW, Stickler GB, et al. Klippel-Trenaunay syndrome: the risks and benefits of vascular interventions. *Surgery* 1991;**110**:469–79
- Lee BB, Kim HH, Mattassi R, Yakes W, Loose D, Tasnadi G. A new approach to the congenital vascular malformation with new concept – Seoul Consensus. *Int J Angiol* 2003;**12**:248–51
- Lee BB, Mattassi R, Loose D, Yakes W, Tasnadi G, Kim HH. Consensus on controversial issues in contemporary diagnosis and management of congenital vascular malformation – Seoul Communication. *Int J Angiol* 2004;**13**:182–92
- Lee BB, Bergan JJ. Advanced management of congenital vascular malformations: a multidisciplinary approach. *J Cardiovasc Surg* 2002;**10**:523–33
- Lee BB, Villavicencio L. General considerations. In: Cronenwett JL, Johnston KW, eds. *Congenital Vascular Malformations. Section 9. Arteriovenous Anomalies. Rutherford's Vascular Surgery*. Chapter 68, 7th edn. Philadelphia, PA: Saunders Elsevier, 2010: 1046–64
- Lee BB. Changing concept on vascular malformation: no longer enigma. *Ann Vas Dis* 2008;**1**:11–9
- Lee BB. Advanced management of congenital vascular malformation (CVM). *Int Angiol* 2002;**21**:209–13
- Lee BB. Current concept of venous malformation (VM). *Phlebolympology* 2003;**43**:197–203

- 1101 38 Vollmar JF, Voss E. Vena marginalis lateralis persistens –
1102 die vergessene Vene der Angiologen. *Vasa* 1979;**8**:192
- 1103 39 Mattassi R, Vaghi M. Management of the marginal vein:
1104 current issues. *Phlebology* 2007;**22**:283–6
- 1105 40 Kim YW, Lee BB, Cho JH, Do YS, Kim DI, Kim ES.
1106 Haemodynamic and clinical assessment of lateral
1107 marginal vein excision in patients with a predomi-
1108 nantly venous malformation of the Lower Extremity.
1109 *Eur J Vasc Endovasc Surg* 2007;**33**:122–7
- 1110 41 Eifert S, Villavicencio JL, Kao TC, Taute BM, Rich NM.
1111 Prevalence of deep venous anomalies in congenital vas-
1112 cular malformations of venous predominance. *J Vasc*
1113 *Surg* 2000;**31**:462–71
- 1114 42 Lee BB, Villavicencio L, Kim YW, et al. Primary Budd-
1115 Chiari syndrome: outcome of endovascular manage-
1116 ment for suprahepatic venous obstruction. *J Vasc Surg*
1117 2006;**43**:101–10
- 1118 43 Zamboni P, Pisano L, Mari C, Galeotti R, Feo C, Liboni
1119 A. Membranous obstruction of the inferior vena cava
1120 and Budd-Chiari syndrome. Report of a case. *J Cardio-
1121 vasc Surg (Torino)* 1996;**37**:583–7
- 1122 44 Gillespie DL, Villavicencio JL, Gallagher C, et al. Pres-
1123 entation and management of venous aneurysms.
1124 *J Vasc Surg* 1997;**26**:845–52
- 1125 45 Lee BB. Statues of new approaches to the treatment of
1126 congenital vascular malformations (CVMs) – single
1127 center experiences (Editorial Review). *Eur J Vasc Endo-
1128 vasc Surg* 2005;**30**:184–97
- 1129 46 Lee BB, Laredo J, Lee SJ, Huh SH, Joe JH, Neville R.
1130 Congenital vascular malformations: general diagnostic
1131 principles. *Phlebology* 2007;**22**:253–7
- 1132 47 Lee BB, Mattassi R, Choe YH, et al. Critical role of
1133 duplex ultrasonography for the advanced management
1134 of a venous Malformation (VM). *Phlebology*
1135 2005;**20**:28–37
- 1136 48 Yoshida H, Yusa H, Ueno E. Use of Doppler color flow
1137 imaging for differential diagnosis of vascular malfor-
1138 mations: a preliminary report. *J Oral Maxillofac Surg*
1139 1995;**53**:369–74
- 1140 49 Rak KM, Yakes WF, Ray RL, et al. MR imaging of symp-
1141 tomatic peripheral vascular malformations. *AJR Am J*
1142 *Roentgenol* 1992;**159**:107–12
- 1143 50 Lee BB, Choe YH, Ahn JM, et al. The new role of MRI
1144 (magnetic resonance imaging) in the contemporary
1145 diagnosis of venous malformation: can it replace angio-
1146 graphy? *J Am Coll Surg* 2004;**198**:549–58
- 1147 51 Lee BB, Kim BT, Choi JY, Cazaubon M. Prise en charge
1148 des malformations vasculaires congénitales (MVC) en
1149 2003: rôle de la scintigraphie corps entier dans la sur-
1150 veillance évolutive. *Angéiologie* 2003;**55**:17–26
- 1151 52 Lee BB, Mattassi R, Kim BT, Kim DI, Ahn JM, Choi JY.
1152 Contemporary diagnosis and management of venous
1153 and AV shunting malformation by whole body blood
1154 pool scintigraphy (WBBPS). *Int Angiol* 2004;**23**:355–67
- 1155 53 Lee BB, Mattassi R, Kim BT, Park JM. Advanced man-
agement of arteriovenous shunting malformation
(AVM) with transarterial lung perfusion scintigraphy
(TLPS) for follow-up assessment. *Int Angiol* 2005;**24**:
173–84
- 54 Vaišnytė B, Vajauskas D, Palionis D, et al. Diagnostic
methods, treatment modalities, and follow-up of extra-
cranial arteriovenous malformations. *Medicina (Kaunas)*
2012;**48**:388–98
- 55 Choi JY, Lee KH, Kim SE, Kim BT, Hwang JH, Lee BB.
Quantitative lymphoscintigraphy in post-mastectomy
lymphedema: correlation with circumferential
measurements (abstract). *Kor J Nucl Med* 1997;**31**:262
- 56 Lee BB, Villavicencio JL. Primary lymphedema and
lymphatic Malformation: are they the two sides of the
same coin? *Eur J Vasc Endovasc Surg* 2010;**39**:646–53
- 57 Lee BB, Andrade M, Bergan J, et al. Diagnosis and treat-
ment of primary lymphedema – consensus document
of the International Union of Phlebology (IUP)-2009.
Int Angiol 2010;**29**:454–70
- 58 Lee BB, Laredo J. Contemporary role of lymphoscinti-
graphy: we can no longer afford to ignore! Editorial.
Phlebology 2011;**26**:177–8
- 59 Lee BB, Laredo J, Kim YW, Neville R. Congenital vascu-
lar malformations: general treatment principles. *Phle-
bology* 2007;**22**:258–63
- 60 Mulliken JB, Glowacki J. Hemangiomas and vascular
malformations in infants and children: a classification
based on endothelial characteristics. *Plast Reconstr*
Surg 1982;**69**:412–22
- 61 Mulliken JB, Zetter BR, Folkman J. In vivo character-
istics of endothelium from hemangiomas and vascular
malformations. *Surgery* 1982;**92**:348–53
- 62 Tasnadi G. Epidemiology and etiology of congenital
vascular malformations. *Semin Vasc Surg* 1993;**6**:200–3
- 63 Lee BB. Lymphedema-angiodysplasia syndrome: a pro-
digal form of lymphatic malformation (LM). *Phlebolymp-
hology* 2005;**47**:324–32
- 64 Villavicencio JL. Congenital vascular malformations –
predominantly venous? The syndrome of Klippel-
Trenaunay. *Scope Phlebol Lymphol* 2000;**71**:116–25
- 65 Gloviczki P, Driscoll DJ. Klippel–Trenaunay syndrome:
current management. *Phlebology* 2007;**22**:291–8
- 66 Wu ZQ. Parkes-Weber’s syndrome: report of 5 cases.
Zhonghua Wai Ke Za Zhi 1993;**31**:749–51
- 67 Courivaud D, Delerue A, Delerue C, Boon L, Piette F,
Modiano P. Familial case of Parkes Weber syndrome.
Ann Dermatol Venereol. 2006;**133**(Part 1):445–7
- 68 Lee BB. Lymphedema – diagnosis and treatment.
In: Tredbar, Morgan, Lee, Simonian, Blondeau, eds.
Lymphatic Malformation. Chapter 4. Springer-Verlag
London Limited, 2008: 31–42
- 69 Lee BB. Lymphatic malformation. In: Tredbar, Morgan,
Lee, Simonian, Blondeau, eds. *Lymphedema – Diagnosis
and Treatment*. Chapter 4. Springer-Verlag London
Limited, 2008:31–42
- 70 Belov ST. Congenital agenesis of the deep veins of the
lower extremity: surgical treatment. *J Cardiovasc Surg*
1972;**13**:594
- 71 Raju S, Hollis K, Neglen P. Obstructive lesions of the
inferior vena cava: clinical features and endovenous
treatment. *J Vasc Surg* 2006;**44**:820
- 72 Zamboni P, Cossu A, Carpanese L, Simonetti G,
Massarelli G, Liboni A. The so-called venous
aneurysms. *Phlebology* 1990;**5**:45–50
- 73 Friedman SG, Krishnasasthy KV, Doscher W, Deckoff
SL. Primary venous aneurysms. *Surgery* 1990;**108**:92–5
- 74 Weber J, Daffinger N. Congenital vascular malfor-
mations: the persistence of marginal and embryonal
veins. *Vasa* 2006;**35**:67–77
- 75 Tzuladze II. The selective phlebography of the large
tributaries of the vena cava system in the diagnosis of
venous circulatory disorders in the spinal complex.
Zh Vopr Neurokhir Im N N Burdenko 1999;**2**:8–13
- 76 Zamboni P, Galeotti R, Menegatti E, et al. Chronic cere-
brospinal venous insufficiency in patients with

Q8

Q9

- 1211 multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2009;**80**:392–9
- 1212 77 Loose DA. Die chirurgische Therapie venöser Aneurysmata. *Gefässchirurgie* 2005;**6**:143–50
- 1213 78 Ritter H, Weber J, Loose DA. Venöse Aneurysmen. *VASA* 1993;**22**:105–12
- 1214 79 Mattassi R, Vaghi M. Vascular bone syndrome-angiosteodystrophy: Current Concept. *Phlebology* 2007;**22**:287–90
- 1215 80 Papaioannou T, Stokes I, Kenwright J. Scoliosis associated with limb-length inequality. *J Bone Joint Surg Am* 1982;**64**:59–62
- 1216 81 Kim YW, Do YS, Lee SH, Lee BB. Risk factors for leg length discrepancy in patients with congenital vascular malformation. *J Vasc Surg* 2006;**44**:545–53
- 1217 82 Trop I, Dubois J, Guibaud L, et al. Soft-tissue venous malformations in pediatric and young adult patients: diagnosis with Doppler US. *Radiology* 1999;**212**:841–5
- 1218 83 Dubois J, Patriquin HB, Garel L, et al. Soft-tissue hemangiomas in infants and children: diagnosis using Doppler sonography. *Am J Roentgenol* 1998;**171**:247–52
- 1219 84 Hyodoh H, Hori M, Akiba H, Tamakawa M, Hyodoh K, Hareyama M. Peripheral vascular malformations: imaging, treatment approaches, and therapeutic issues. *RadioGraphics* 2005;**25**:S159–71
- 1220 85 Napoli A, Fleischmann D, Chan FP, et al. Computed tomography angiography: state-of-the-art imaging using multidetectorrow technology. *J Comput Assist Tomogr* 2004;**28**(Suppl 1):S32–45
- 1221 86 Gloviczki P, ed. *Summary of Guideline of American Venous Forum: 706–722, Handbook of Venous Disorders*, 3rd edn. London, UK: A Hodder Arnold, 2008
- 1222 87 Baker LL, Dillon WP, Hieshima GB, Dowd CF, Frieden IJ. Hemangiomas and vascular malformations of the head and neck: MR characterization. *AJNR Am J Neuroradiol* 1993;**14**:307–14
- 1223 88 Gelbert F, Riche MC, Reizine D, et al. MR imaging of head and neck vascular malformations. *J Magn Reson Imaging* 1991;**1**:579–84
- 1224 89 Inoue Y, Wakita S, Ohtake T, et al. Use of whole-body imaging using Tc-99m RBC in patients with soft-tissue vascular lesions. *Clin Nucl Med* 1996;**21**:958–9
- 1225 90 Fukuda Y, Murata Y, Umehara I, et al. Perfusion and blood pool scintigraphy for diagnosing soft-tissue arteriovenous malformations. *Clin Nucl Med* 1999;**24**:232–4
- 91 Neglen P. Chronic deep venous obstruction: definition, prevalence, diagnosis, management. *Phlebology* 2008;**23**:149–57
- 92 Neglen P, Raju S. Intravascular ultrasound scan evaluation of the obstructed vein. *J Vasc Surg* 2002;**35**:694–700
- 93 Nicolaides AN, Allegra C, Bergan J, et al. Management of chronic venous disorders of the lower limbs: guidelines according to scientific evidence. *Int Angiol* 2008;**27**:1–60
- 94 Mazereeuw-Hautier J, Syed S, Leisner RI, et al. Extensive venous/lymphatic malformations causing life-threatening haematological complications. *Br J Dermatol* 2007;**157**:558–62
- 95 Hermans C, Dessomme B, Lambert C, et al. Venous malformations and coagulopathy. *Ann Chir Plast Esthet* 2006;**51**:388–93
- 96 Redondo P, Aguado L, Marquina M. Angiogenic and prothrombotic markers in extensive slow-flow vascular malformations: implications for antiangiogenic/ antithrombotic strategies. *Br J Dermatol* 2010;**162**:350–6
- 97 Mazoyer E, Enjolras O, Bisdorff A, et al. Coagulation disorders in patients with venous malformation of limbs and trunk: a study in 118 patients. *Arch Dermatol* 2008;**144**:861–7
- 98 Domp Martin A, Acher A, Thibon P, et al. Association of localized intravascular coagulopathy with venous malformations. *Arch Dermatol* 2008;**144**:873–7
- 99 Domp Martin A, Ballieux F, Thibon P, et al. Elevated D-dimer level in the differential diagnosis of venous malformations. *Arch Dermatol* 2009;**145**:1239–44
- 100 Prisco D, Grifoni E. The role of D-dimer testing in patients with suspected venous thromboembolism. *Semin Thromb Hemost* 2009;**35**:50–9
- 101 Falanga V, Kruskal J, Franks JJ. Fibrin- and fibrinogen-related antigens in patients with venous disease and venous ulceration. *Arch Dermatol* 1991;**127**:75–8
- 102 Xu G, Tian KL, Liu GP, Zhong XJ, Tang SL, Sun YP. Clinical significance of plasma D-dimer and von Willebrand factor levels in patients with ulcer colitis. *World J Gastroenterol* 2002;**8**:575–6
- 103 Gouin-Thibault I, Arkam R, Nassiri S, et al. Markers of activated coagulation in patients with factor V Leiden and/or G20210A prothrombin gene mutation. *Thromb Res* 2002;**107**:7–11

QUERY FORM

Royal Society of Medicine

Journal Title: **PHLEB**

Article No: **475960**

AUTHOR: The following queries have arisen during the editing of your manuscript. Please answer the queries by making the requisite corrections at the appropriate positions in the text.

Query No.	Nature of Query	Author's Response
Q1	Please provide a maximum of five keywords.	
Q2	Please provide complete address of the author in correspondence field.	
Q3	Please provide the History details.	
Q4	You have opted for colour figures when submitting your manuscript. Though the article figures will be in colour when published online, there is an associated charge for colour figures in the published print version. If you would like to opt for this colour option in print, please confirm which figures are applicable and we will send you further information.	
Q5	Please check what (5) stands for in the sentence 'However, t2-weighted....'. Is it a reference?	
Q6	As per journal style cross-references not allowed in section headings, shifted to text, please check whether the placement of cross-citation is suitable.	
Q7	Please provide year and place of publishing in ref. 14.	
Q8	Please provide initials of editors and location for reference 68 and 69	
Q9	References 68 and 69 are similar, please check refs. 68 and 69 correctly set.	